Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome

American Journal of Transplantation

Volumn 7, Issue 2, 2007, Pages 476-479

  Levi, Z ^a   Hazazi, R ^a   Kedar Barnes, I ^a   Hodak, E ^a   Gal, E ^a   Mor, E ^a   Niv, Y ^a   Winkler, J ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Tumor recurrence

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN MSH2; RAPAMYCIN; TACROLIMUS;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER REGRESSION; CASE REPORT; COLON CANCER; DRUG SUBSTITUTION; GENE MUTATION; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MENTAL CONCENTRATION; MUIR TORRE SYNDROME; MUSCLE CRAMP; PRIORITY JOURNAL; PRURITUS; SEBACEOUS GLAND TUMOR; SIDE EFFECT; WEAKNESS;

ADENOMA; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; SEBACEOUS GLAND NEOPLASMS; SIROLIMUS; SYNDROME; TACROLIMUS;

EID: 33846260721     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01648.x     Document Type: Article

References (23)

1. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JPA. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-406.
2. Jensen P, Hansen S, Moller B, Leiestad T, Pfeffer P, Geiran O. Skin cancer in kidney and heart transplant recipients and different long term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-186.
3. Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: The Muir-Torre syndrome. Am J Med 1991; 90: 606-613.
4. Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005; 6: 980-987.
5. Lynch HT, Lynch PM, Pester J, Fusaro RM. The cancer family syndrome: Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med 1981; 141: 607-611.
6. Fusaro RM, Lemon SJ, Lynch HT. The Muir-Torre syndrome: A variant of the hereditary nonpolyposis colorectal cancer syndrome. J Tumor Marker Oncol 1996; 11: 19-31.
7. Kolodner RD, Hall NR, Lipford J et al. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for MSH2 mutations. Genomics 1994; 24: 516-526.
8. Dover JS, Ashur ML, Kwan TH. Sebaceous adenoma in a patient with acquired immunodeficiency syndrome. Arch Dermatol 1988; 124: 489-490.
9. Warschaw KE, Eble JN, Hood AF, Wolverton SE, Halling KC. The Muir-Torre syndrome in a black patient with AIDS: Histopathology and molecular genetic studies. J Cutan Pathol 1997; 24: 511-518.
10. Graells J, Marcoval M, Badell A, Notario J, Fulladosa X. Muir-Torre syndrome in a patient with acquired immunodeficiency syndrome. Br J Dermatol 1996; 135: 159-161.
11. Glover MT, Niranjan N, Kwan JTC, Leigh IM. Non-melanoma skin cancer in renal transplant recipients: The extent of the problem and a strategy for management. Br J Plast Surg 1994; 47: 86-89.
12. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancer in renal-transplant recipients occur more frequently than previous recognized in a temperate climate. Transplantation 2004; 77: 574-579.
13. Harwood CA, McGregor JM, Swale VJ et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol 2003; 48: 401-408.
14. Harwood CA, Swale VJ, Bataille VA et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. J Invest Dermatol 2001; 116: 246-253.
15. Stone MS, Duncan WC, McGavran MH. Torre's syndrome: Exacerbation of cutaneous manifestations with immunosuppression. J Am Acad Dermatol 1986; 15: 1101-1103.
16. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
17. Campistol J, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762.
18. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
19. Law BK, Chytil A, Dumont N et al. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene- transformed, and human cancer cells, Mol Cell Biol 2002; 22: 8184-8198.
20. Perl AK, Wilgenbus P, Dahl U et al. A causal role for E-cadherin in the transition from adenoma to carcinoma, Nature 1998; 392: 190-193.
21. Sodhi A, Chaisuparat R, Hu J et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10: 133-143.
22. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 2005; 56: 71-85.
23. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913.